Head and Neck Cancer
NRG-HN010
Official Title: Testing the use of ado-trastuzumab emtansine compared to the usual treatment (chemotherapy with docetaxel plus trastuzumab) for recurrent, metastatic, or unresectable HER2-Positive salivary gland cancer.
Study Purpose: Will ado-trastuzumab emtansine extend the length of time without your cancer getting worse compared to standard of care?
Status:
Recruiting